Related references
Note: Only part of the references are listed.CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
H. Frangoul et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics
Niels Dammes et al.
NATURE NANOTECHNOLOGY (2021)
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Julian D. Gillmore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer et al.
SCIENCE (2020)
Gene editing and CRISPR in the clinic: current and future perspectives
Matthew P. Hirakawa et al.
BIOSCIENCE REPORTS (2020)
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing
Qiang Cheng et al.
NATURE NANOTECHNOLOGY (2020)
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Lei Xu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Search-and-replace genome editing without double-strand breaks or donor DNA
Andrew V. Anzalone et al.
NATURE (2019)
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Alexis C. Komor et al.
NATURE (2016)
Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene Delivery
Christian J. Buchholz et al.
TRENDS IN BIOTECHNOLOGY (2015)
The new frontier of genome engineering with CRISPR-Cas9
Jennifer A. Doudna et al.
SCIENCE (2014)
Share Paper
